These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 18314477

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
    Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, Kim JJ.
    Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK, Hung HF, Duffy S, Yen AM, Chen HH.
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
    Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C.
    Gynecol Oncol; 2009 Feb; 112(2):377-83. PubMed ID: 19081611
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.
    Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P.
    Can J Public Health; 2010 Feb; 101(3):220-5. PubMed ID: 20737813
    [Abstract] [Full Text] [Related]

  • 12. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP.
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
    Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, Ieumwananonthachai N, Tangcharoensathien V.
    Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
    Kim JJ, Burger EA, Sy S, Campos NG.
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.